Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF FINANCIAL OFFICER | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,494 |
Ending reported balance
After 2026-02-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 5,332 · Balance 38,290 Row 2 · 2026-02-20 · Tax withholding · Disposed 2,876 · Balance 35,414 F1: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Row 3 · 2026-02-23 · Exercise / conversion · Acquired 6,688 · Balance 42,102 Row 4 · 2026-02-23 · Tax withholding · Disposed 3,608 · Balance 38,494 F2: The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,995 |
Reported balance
After 2026-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-20 · Exercise / conversion · Disposed 5,332 · Balance 15,995 F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 36,357 |
Reported balance
After 2026-02-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-23 · Exercise / conversion · Disposed 6,688 · Balance 36,357 F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2: The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2026 Filed Feb 24, 2026 23:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 6,688 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000029 · wk-form4_1771974883.xml · derivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,357 Underlying: Common Stock · 6,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,608 | $70.64 | $254,869.12 |
DisclosureSEC source: 0001159036-26-000029 · wk-form4_1771974883.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,494 F2 · shares: The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000029 · wk-form4_1771974883.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000029 · wk-form4_1771974883.xml · derivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,995 Underlying: Common Stock · 5,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,876 | $70.98 | $204,138.48 |
DisclosureSEC source: 0001159036-26-000029 · wk-form4_1771974883.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,414 F1 · shares: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000029 · wk-form4_1771974883.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 13,351 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · derivative · entry 9 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,351 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · derivative · entry 8 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,329 Underlying: Common Stock · 5,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,093 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · derivative · entry 7 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 7,273 | $79.44 | $577,767.12 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · nonDerivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,958 F3 · shares: The reported disposition of 7,273 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 13,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · nonDerivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,874 | $79.44 | $228,310.56 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,880 F2 · shares: The reported disposition of 2,874 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,747 | $79.44 | $218,221.68 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,425 F1 · shares: The reported disposition of 2,747 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000026 · wk-form4_1771372364.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 29,502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000015 · wk-form4_1770862831.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,502 Underlying: Common Stock · 29,502 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 7,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000015 · wk-form4_1770862831.xml · derivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,045 Underlying: Common Stock · 7,448 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 5,167 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000015 · wk-form4_1770862831.xml · derivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,351 Underlying: Common Stock · 5,167 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| September 22, 2025 Filed Sep 23, 2025 20:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 314 | $78.67 | $24,701.44 |
DisclosureSEC source: 0001910662-25-000003 · form4-09232025_080958.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,079 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $78.37 to $79.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 22, 2025 Filed Sep 23, 2025 20:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,913 | $77.83 | $148,883.05 |
DisclosureSEC source: 0001910662-25-000003 · form4-09232025_080958.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,393 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $77.34 to $78.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,135 | $0.00 Strike: $12.49 | $0.00 |
DisclosureSEC source: 0001415889-25-024295 · form4-09112025_090953.xml · derivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 812 Underlying: Common Stock · 1,135 shares Expires 2027-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F5 · derivative.exercise_date: This option was granted on August 1, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 11,271 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-25-024295 · form4-09112025_090953.xml · derivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,271 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F4 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 13,240 | $75.93 | $1,005,299.96 |
DisclosureSEC source: 0001415889-25-024295 · form4-09112025_090953.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,306 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $75.56 to $76.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 6,760 | $75.29 | $508,967.16 |
DisclosureSEC source: 0001415889-25-024295 · form4-09112025_090953.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,546 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $74.56 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,135 | $12.49 | $14,176.15 |
DisclosureSEC source: 0001415889-25-024295 · form4-09112025_090953.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 11,271 | $12.07 | $136,040.97 |
DisclosureSEC source: 0001415889-25-024295 · form4-09112025_090953.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,688 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005299 · form4-02242025_100217.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,063 Underlying: Common Stock · 6,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,601 | $57.75 | $207,957.75 |
DisclosureSEC source: 0001415889-25-005299 · form4-02242025_100217.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,900 F1 · shares: The reported disposition of 3,601 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005299 · form4-02242025_100217.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 21,327 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005173 · form4-02212025_110257.xml · derivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,327 Underlying: Common Stock · 21,327 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 22,603 | $0.00 Strike: $57.44 | $0.00 |
DisclosureSEC source: 0001415889-25-005173 · form4-02212025_110257.xml · derivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,603 Underlying: Common Stock · 22,603 shares Expires 2035-02-20 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · derivative · entry 12 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,658 Underlying: Common Stock · 5,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,093 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · derivative · entry 11 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,093 Underlying: Common Stock · 5,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 17,409 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · derivative · entry 10 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. F6 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,869 | $58.29 | $167,234.01 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 8 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,813 F4 · shares: The reported disposition of 2,869 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 7 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,742 | $58.29 | $159,831.18 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,353 F3 · shares: The reported disposition of 2,742 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 9,400 | $58.29 | $547,926.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,002 F2 · shares: The reported disposition of 9,400 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 17,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · derivative · entry 9 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 741 | $58.29 | $43,192.89 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,993 F1 · shares: The reported disposition of 741 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004507 · form4-02182025_110210.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 28,662 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004237 · form4-02142025_110239.xml · derivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,662 Underlying: Common Stock · 28,662 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Unit · Derivative | 6,935 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004237 · form4-02142025_110239.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,935 Underlying: Common Stock · 6,935 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 5,221 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004237 · form4-02142025_110239.xml · derivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,184 Underlying: Common Stock · 5,221 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 6,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004237 · form4-02142025_110239.xml · derivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,409 Underlying: Common Stock · 6,050 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 20:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,000 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001415889-24-019936 · form4-07232024_080706.xml · derivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F4 · derivative.exercise_date: This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 20:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 992 | $54.25 | $53,818.98 |
DisclosureSEC source: 0001415889-24-019936 · form4-07232024_080706.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,480 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.17 to $54.325. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 20:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 992 | $22.50 | $22,320.00 |
DisclosureSEC source: 0001415889-24-019936 · form4-07232024_080706.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.